NAFLD / NASH
"Tocotrienols address multiple steps in the NAFLD/NASH cascade including the abnormal retention of fat in liver cells (steatosis), the inflammation caused by the steatosis and the generation of scar tissue (fibrosis/cirrhosis) that results from inflammation.
Clinical studies in another group have demonstrated that orally delivered tocotrienols have shown efficacy in addressing NAFLD/NASH. By delivering the tocotrienols directly and in a non-invasive way using AZT's transmucosal delivery platform, we are exploring an exciting potential new therapy for NAFLD/NASH.
The non-invasive delivery method maximises patient compliance which is really important for a chronic disease like NAFLD/NASH."
Professor Edward Gane
MBCHB, MD, FRACP, MNZM, FRSNZ, international expert on hepatology and Member of AZT's Scientific Advisory Board
“…financial analysts predict that by 2025, the drug market for NAFLD will be worth $20 billion to $35 billion a year. And so far, no drug has been specifically approved for treating the condition.”
Ref: https://www.nature.com/articles/d41586-017-06926-1
Tocotrienols are strong antioxidants and have anti-fibrotic activity. They distribute preferentially to the liver and there is clinical evidence of efficacy. There are no medicines currently approved for the treatment of NAFLD/NASH. This situation creates an unmet medical need for an effective and well tolerated treatment for NAFLD/NASH.
ABN 35 111 082 485